Use of Medication Assisted Treatment for Opioid Use Disorder During Pregnancy

The WSMA acknowledges the risks of Opioid Use Disorder (OUD) during pregnancy for both mother and fetus. The WSMA supports universal screening with validated screening tools, in conjunction with the Screening Brief Intervention and Referral to Treatment (SBIRT) model, and utilization of multidisciplinary care in the treatment of these patients. (C-14, A-21)

That the WSMA supports the use of medication for opioid use disorder (MOUD) in the pregnant population. (C-14, A-21)

The WSMA supports expansion of the chemical-using pregnant women program to more institutions, including in Eastern Washington. The WSMA supports legislation that grants pregnant women priority in publicly-funded treatment programs and protects them from discrimination in these programs. (C-14, A-21)

Return to the WSMA Policy Compendium index

Abbreviations for House of Delegates report origination:

EC – Executive Committee; BT – Board of Trustees; CPA – Council on Professional Affairs; JC – Judicial Council; CHS – Community and Health Services